Yahoo · Sep 3, 2026
Here's Why You Should Add RNTX Stock to Your Portfolio Now
Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
AL
NASDAQ · ALDX
Aldeyra Therapeutics, Inc.
Healthcare · Biotechnology
$1.37
Up+$0.03 (+2.50%)
Updated Sep 17, 2026, 3:54 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 328.49M
- P/E ratio
- -7.6
- Dividend yield
- 0.00%
- 52-week range
- $1.07 – $5.60
- Volume
- 791.86K
- Avg. volume
- 1.07M
Price performance
ALDX price history
1M range · 20 trading sessions · Daily adjusted prices
ALDX closed at $1.37 after 20 trading sessions, down 13.29% for the selected period.
- Last close
- $1.37
- Period change
- -13.29%
- Period low
- $1.34
- Period high
- $1.58
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.38 | $1.40 | $1.355 | $1.37 | 791.86K |
| Sep 15, 2026 | $1.45 | $1.45 | $1.345 | $1.37 | 833.61K |
| Sep 14, 2026 | $1.35 | $1.49 | $1.3475 | $1.46 | 1.17M |
| Sep 11, 2026 | $1.48 | $1.48 | $1.33 | $1.34 | 1.57M |
| Sep 10, 2026 | $1.48 | $1.505 | $1.46 | $1.46 | 552.54K |
| Sep 9, 2026 | $1.53 | $1.535 | $1.495 | $1.50 | 544.21K |
| Sep 8, 2026 | $1.47 | $1.55 | $1.47 | $1.54 | 721.82K |
| Sep 4, 2026 | $1.47 | $1.49 | $1.46 | $1.48 | 486.18K |
| Sep 3, 2026 | $1.48 | $1.5111 | $1.46 | $1.48 | 568.93K |
| Sep 2, 2026 | $1.51 | $1.54 | $1.46 | $1.49 | 498.45K |
| Sep 1, 2026 | $1.46 | $1.50 | $1.455 | $1.49 | 462.87K |
| Aug 31, 2026 | $1.51 | $1.51 | $1.465 | $1.48 | 495.39K |
| Aug 28, 2026 | $1.52 | $1.56 | $1.48 | $1.485 | 547.98K |
| Aug 27, 2026 | $1.57 | $1.581 | $1.525 | $1.54 | 277.45K |
| Aug 26, 2026 | $1.54 | $1.575 | $1.52 | $1.56 | 478.95K |
| Aug 25, 2026 | $1.52 | $1.56 | $1.50 | $1.55 | 447.17K |
| Aug 24, 2026 | $1.53 | $1.545 | $1.4601 | $1.52 | 531.99K |
| Aug 21, 2026 | $1.50 | $1.595 | $1.475 | $1.52 | 1.1M |
| Aug 20, 2026 | $1.57 | $1.575 | $1.495 | $1.50 | 942.95K |
| Aug 19, 2026 | $1.59 | $1.60 | $1.54 | $1.58 | 982.2K |
Latest ALDX news
The latest Smart Investors Daily articles mentioning ALDX.
Stock researchCompany · Overview
ALDX research
Overview
Company profile and research snapshot.
Company profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 10, 2025 | BTIG | Buy | — |
| May 19, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2025 | BTIG | Buy | — |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.
Benzinga · Jul 15, 2026
Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026
SEC Filing
SeekingAlpha · Jul 10, 2026
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL
Aldeyra Therapeutics plunges after a third FDA CRL for reproxalap. Click here to read my most recent analysis of Aldeyra Therapeutics stock.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
